To print: Select File and then Print from your browser's menu

Title: Alefacept Therapy May Result In Prolonged Psoriasis Remission Through Reduction Of T-Cell Subsets

URL:

Archives of Dermatology 2003;139:1563-1570.
12/16/2003 02:17:00 PM
By Elda Hauschildt

Alefacept therapy reduces levels of circulating memory T-cell subsets in patients with psoriasis and can lead to prolonged disease remission, research in North America indicates. One or 2 courses of intravenous alefacept reduced CD4[⁺ and CD8⁺ memory T-cell counts in a study of 553 psoriasis patients, 16 years or older, who had moderate-to-severe, stable plaque psoriasis for at least 12 months. Their disease involved at least 10% of body surface area, and patients had normal CD4⁺ lymphocyte counts. Participants were treated at 51 study centres in the United States and Canada. "The reduction in levels of circulating memory T-cell subsets with alefacept treatment correlates to improvement in psoriasis and suggests a relationship between the length of response to alefacept and alterations in the memory T-cell population," report researchers led by Dr. Kenneth Gordon of Loyola University Medical Centre in Maywood, Illinois, United States. They explain that scientific and clinical evidence had already pointed to a pivotal role for the T-cell in psoriasis. Their data "strongly" support this central role of memory T-cells, as well as the potential efficacy advantages of targeting effector cells in treating the disease. Participants were randomised to 1 of 3 cohorts on a 1:1:1 basis. Cohort 1 received 7.5 milligrams of alefacept in both of 2 drug courses; cohort 2 took 7.5 mg of alefacept in the first and placebo in the second course. Cohort 3 took placebo in the course and 7.5 mg of alefacept in the second course. Nine treatments were prohibited within 4 weeks of alefacept administration and during the study: phototherapy, systemic retinoids, systemic steroids, systemic fumarates, methotrexate, cyclosporine, azathioprine, thioguanine or high-potency topical corticosteroids. Moderate-potency topical corticosteroids, vitamin D analogues, keratolytics and coal tar use were prohibited within 2 weeks of drug administration and throughout the study, except on the scalp, palms, groin, anal fold and soles. Except within 12 hours of efficacy assessments, sparing use of low-potency topical corticosteroids and emollients was permitted. At 12 weeks following the last course 1 alefacept dose, 88% of patients had CD4⁺ cell counts greater than the lower normal limit. At 12 weeks following the last course 2 alefacept dose, 83% of patients had reached this marker. Patients with the largest decreases in memory T-cell counts through course 1 alefacept therapy experienced the greatest reductions in disease activity

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.